Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 69.53

-1.0%

Nov 7 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (118)	11/20/2002 3:25:27 PM
From: Jibacoa	Read Replies (1) of 3722

GNVC Is up 23.36% on volume of 353,370 ( about 13x its daily average) after it said that a Phase II study of Biobypass angiogen showed significant positive results in patients with severe artery disease. Patients were randomized into two groups where 36 were treated with Biobypass and 35 served as a control group.(The two groups otherwise received the same medical treatment.)GenVec said the the Biobypass group showed "significant improvement in all endpoints". biz.yahoo.com siliconinvestor.com siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next